Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

Bristol-Myers Squibb (BMS) building

BMS to publish full clinical study reports in transparency drive

Partners with Duke University to grant access back to 2008

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

- PMLiVE

Takeda drops prostate cancer drug in phase III

Suffers another late-stage pipeline blow as orteronel disappoints

- PMLiVE

Allergan and taking a specialised approach

Pharma interview: Paul Navarre and Paul Boland talk about how the company, best known for Botox, is looking to create a culture of growth

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

Pharma investment in marketing flat in 2013

And top 10 companies reduced yearly spend on sales force and marketing channels

- PMLiVE

Allergan rebuffs Valeant once again

Could lead to hostile takeover bid

- PMLiVE

GSK takes anti-inflammatory drug into phase III as heart therapy

Studies losmapimod’s potential in acute coronary syndrome

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links